SCHEMBL6073958

SCHEMBL6073958

C[C@@H]1CN(c2ccc(Nc3ncc4cc(F)c(NC(=O)NC(C)(C)C)nc4n3)cc2)C[C@H](C)N1C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 7/20 0.41
FGFR2 P21802 3/20 0.41
FGFR4 P22455 3/20 0.41
FGFR3 P22607 3/20 0.41
JAK3 P52333 2/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
EGFR P00533 2/20 0.40
SYK P43405 3/20 0.39
CCND3 P30281 2/20 0.39
CCNK O75909 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CDK9 P50750 1/20 0.39
CDK6 Q00534 1/20 0.39
PDGFRB P09619 2/20 0.39
SRC P12931 2/20 0.39
PDGFRA P16234 2/20 0.39
CDK4 P11802 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6073961 1.00 FGFR1 (0.41) FGFR1FGFR2FGFR4FGFR3JAK3
SCHEMBL6073729 0.91 FGFR1 (0.46) FGFR1FGFR2FGFR4FGFR3EGFR
SCHEMBL6074187 0.91 FGFR1 (0.41) FGFR1FGFR2FGFR4FGFR3JAK3
SCHEMBL6073735 0.91 FGFR1 (0.46) FGFR1FGFR2FGFR4FGFR3EGFR
SCHEMBL6074180 0.91 FGFR1 (0.41) FGFR1FGFR2FGFR4FGFR3JAK3
SCHEMBL6073827 0.89 CCND3 (0.41) FGFR1FGFR2FGFR4FGFR3JAK3
SCHEMBL6073824 0.89 CCND3 (0.41) FGFR1FGFR2FGFR4FGFR3JAK3
SCHEMBL6073724 0.86 FGFR1 (0.44) FGFR1FGFR2FGFR4FGFR3JAK2
SCHEMBL6073732 0.86 FGFR1 (0.44) FGFR1FGFR2FGFR4FGFR3JAK2
SCHEMBL6073388 0.86 SYK (0.40) FGFR1FGFR2FGFR4FGFR3JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 FGFR1 280/4885FGFR2 273/4885FGFR4 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.